schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals."
.
please wait�
.
written reports, including local media accounts, professional medical papers and internal emails were also examined.
.
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.